This webinar will review the key design and primary and secondary outcomes from NIDA Clinical Trials Network Study 0080. This landmark study randomized 140 pregnant adults with moderate-severe OUD across multiple collaborative care addiction and OB/GYN treatment programs. Participants were randomized to either extended-release buprenorphine or sublingual buprenorphine. Study treatment was provided through delivery and for 12 months post-partum. Comprehensive effectiveness and safety outcomes for the participating mothers and babies will be shared and discussed.